Abstract
AD accounts for up to 75 % of all dementia cases. The differential diagnosis with other conditions is sometimes challenging since several disorders may produce similar symptoms to AD. Several CSF proteins are useful in the differential diagnosis between the neurodegenerative disorders causing dementia; however, there is some overlap among the proteins accumulated in various neurodegenerative, limiting the utility of such measures in the differential diagnosis of dementia. Medial temporal lobe atrophy on MRI and positive amyloid PET scans may be also useful to distinguish AD from other dementias in some cases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O’Brien JT (1999) Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 52:1153–1158
Burton EJ, Barber R, Mukaetova-Ladinska EB, Robson J, Perry RH, Jaros E et al (2009) Medial temporal lobe atrophy on MRI differentiates Alzheimer’s disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 132(Pt 1):195–203
de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R et al (2011) Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer’s disease from other cortical dementias. J Neurol Neurosurg Psychiatry 82:240–246
Irwin DJ, Trojanowski JQ, Grossman M (2013) Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer’s disease. Front Aging Neurosci 5:6
Ishii K, Soma T, Kono AK, Sofue K, Miyamoto N, Yoshikawa T et al (2007) Comparison of regional brain volume and glucose metabolism between patients with mild dementia with Lewy bodies and those with mild Alzheimer’s disease. J Nucl Med 48:704–711
Kasanuki K, Iseki E, Fujishiro H, Yamamoto R, Higashi S, Minegishi M et al (2012) Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies. J Neurol Sci 314:111–119
Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M et al (2009) The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 50:1638–1645
Lu PH, Mendez MF, Lee GJ, Leow AD, Lee HW, Shapira J et al (2013) Patterns of brain atrophy in clinical variants of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 35:34–50
Madhavan A, Whitwell JL, Weigand SD, Duffy JR, Strand EA, Machulda MM et al (2013) FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer’s type. PLoS One 8:e62471
Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G et al (2008) Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med 49:390–398
O’Donovan J, Watson R, Colloby SJ, Firbank MJ, Burton EJ, Barber R et al (2013) Does posterior cortical atrophy on MRI discriminate between Alzheimer’s disease, dementia with Lewy bodies, and normal aging? Int Psychogeriatr 25:111–119
Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N et al (2011) Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 77:2034–2042
Seeley WW, Miller BL (2013) Alzheimer’s disease and other dementias. In: Hauser SL (ed) Harrison’s neurology in clinical medicine, 3rd edn. McGraw-Hill Education, New York, pp 310–332
Tam CW, Burton EJ, McKeith IG, Burn DJ, O’Brien JT (2005) Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 64:861–865
van de Pol LA, Hensel A, van der Flier WM, Visser PJ, Pijnenburg YA, Barkhof F, Gertz HJ et al (2006) Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer’s disease. J Neurol Neurosurg Psych 77:439–442
van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, van de Berg WD (2013) Reduced α-synuclein levels in cerebrospinal fluid in Parkinson’s disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol. doi:10.1111/ene.12176
Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Boström F et al (2013) Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 8:e53250
Yamane T, Ikari Y, Nishio T, Ishii K, Ishii K, Kato T et al (2013) Visual-statistical interpretation of 18F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation. Am J Neuroradiol. doi:10.3174/ajnr.A3665
Zhang J, Mattison HA, Liu C, Ginghina C, Auinger P, McDermott MP et al (2013) Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol 126:671–678
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Menéndez González, M. (2014). Differential Diagnosis. In: Atlas of Biomarkers for Alzheimer's Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-07989-9_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-07989-9_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-07988-2
Online ISBN: 978-3-319-07989-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)